EQUASENS GROUP: 2022 third-quarter revenue
Villers-lès-Nancy, 9 November 2022 - 6:00 p.m.
(CET)
PRESS RELEASE
2022 third-quarter revenue
-
Q3 2022 revenue: +13.39 % to
€50.13m.
- Nine-month
growth momentum remains on track: +11.29 % to
€153.70m.
- The Group
confirms that this level will be maintained for the 2022 full
year.
In €m |
2021 |
2022 |
Change2022/2021 |
Q1 |
45.27 |
49.36 |
+ 9.03 % |
Q2 |
48.63 |
54.21 |
+ 11.48 % |
Q3 (unaudited) |
44.21 |
50.13 |
+ 13.39 % |
9 month YTD |
138.11 |
153.70 |
+ 11.29 % |
Equasens Group achieved excellent performances
in Q3 2022 with revenue reaching €50.13m, +13.39 % from
Q3 2021 (€44.21m).
On a like-for-like basis (excluding the
acquisition of PROKOV EDITIONS), Q3 2022 revenue grew 9.94% from
last year’s third quarter to €48.61m.
Growth by all Divisions (while the FINTECH
ecosystem remained impacted by challenging market conditions).
For the first nine months, Equasens Group’s
consolidated revenue reached €153.70m, +11.29 % in relation to
the same period in 2021. Like-for-like (excluding PROKOV EDITIONS’
acquisition), revenue year-to-date was €149.72m, +8.40 %
compared to the first nine months of 2021.
Operating highlights by Division at 30 September
2022
-
PHARMAGEST
Division: Q3 2022, +10.51 % to
€36.86m. At 30/09/2022, +7.96 % to €112.67m. This Division accounts
for 73.53 % of total Group revenue.
-
France: Q3 2022, +10.45 % to €33.13m. At
30/09/2022, +7.24 % to €100.94m.
In parallel with the electronic labelling
activity, which is continuing to perform well, and pending the
introduction of new functionalities linked to developments linked
to the French Digital Healthcare investment programme (Ségur), this
Business Unit is also rolling out new solutions: id.Mobilité (the
ergonomic touch terminal that makes it possible to gain in agility
and facilitates logistics in the pharmacy) as well as the new
OffiSecure Fibre formula (integrating an advanced cybersecurity
system).
-
Italy: Q3 2022, +13.43 % to €2.57m. At 30/09/2022,
+16.41 % to €7.87m.
Growth momentum is
continuing both for pharmacies driven by the investment plan
(strengthening of the sales team, opening of new outlets) and for
wholesaler-distributors supported by the effectiveness of the
Farmaclick® ordering platform. The opening of the market for the
manual dispensing solution should accelerate sales of MultiMeds
manual pill dispensers, the only solution present in this market in
Italy, and boost sales for pharmacies.
-
Belgium: Q3 2022 down 6.14 % to €0.56m. At
30/09/2022, +6.92 % to €1.94m.
Investments by
pharmacies and pharmacy groups continue to be limited by the
uncertain economic environment which is delaying the commercial
roll-out of the new id. brand offering and the launch of the
electronic labelling activity.
- Digital
Communication: Q3 2022, +20.71 % to €0.59m. At
30/09/2022, +15.55 % to €1.92m.
This Business Unit has
successfully identified its market and provides dedicated services
fully adapted to the marketing strategies and expenditures incurred
by pharmacists, manufacturers and pharmaceutical groups.
- AXIGATE
LINK Division: Q3 2022, +17.47 % to €7.47m. At
30/09/2022, +11.24 % to €22.61m. This Division accounts for
14.91 % of total Group revenue.
The positive momentum that began in Q2 is
continuing in response to the qualification of virtually all the
Division's software solutions (DOMILINK HAD, HOSPILINK, MEDILINK,
TITAN) for the three market segments of the Ségur programme:
- Nursing
home sector: Q3 2022, +25.43 % to €3.72m. At 30/09/2022,
+12.99 % to €11.40m;
- The
Hospital-at-Home (HaH)
care sector: Q3 2022, +14.16 % to €1,41m. At 30/09/2022,
+6.23 % to €4.08m;
-
Hospitals: Q3 2022 down 4% to €1,03m. At
30/09/2022, +3.64 % to €3.17m;
- the
Healthcare Establishment and Private Practice: Q3
2022, +21.60 % to €1,18m. At 30/09/2022, +15.95 % to €3.53m
pandaLAB Pro's recent certification reinforces the Group's strategy
of promoting interconnectivity and should accelerate the
application's deployment in specific private ecosystems.
The Telemedicine business'
growth momentum (0.26% of total Group revenue) remains on track:
+12.24% in Q3 2022 to €0.13m and +46.15% at 30/09/2022 to €0.44m.
The Division's sales forces are fully focused on promoting the
CARELIB EHPAD and ETPLINK solutions and developing new modules (the
interconnection of CARELIB EHPAD nursing home application with DECT
equipment and the creation of new functionalities for ETPLINK for
the management of outpatient hospital care).
-
E-CONNECT
Division: Q3 2022 down 2.96% to
€3.83m. At 30/09/2022, +11.84 % to €12.91m. This Division
accounts for 7.64 % of total Group revenue.
- In the
Frailty Management sector, the Division is
continuing to promote its new homecare product LIVIAHOME by
NOVIAcare and is multiplying contacts with partners and
distributors, with homecare a priority both in France and in
Europe.
- While growth of the
Compliance has remained steady, the
e-Connect
Business Unit
has experienced a marginal slowdown. Supply chain difficulties for
electronic components continue to be a major issue adversely
affecting the BU's activity. By anticipating these market
challenges and implementing a CSR strategy to improve equipment
remanufacturing, the e-Connect Business Unit is able to meet its
production capacity and deadlines.
- MEDICAL
SOFT Division (which includes the PROKOV EDITIONS
business integrated in Q4 2021): PROKOV EDITIONS announced Q3 2022
revenue of €1.52m. As at 30/09/2022, year-to-date revenue reached
€3.98m. This Division accounts for 3.04 % of total Group
revenue.
PROKOV EDITIONS was
the first company in the market to obtain Ségur certification for
its medical software and began implementing its action plan in
June:
- business
development and marketing initiatives to promote and sell MédiStory
4's functionalities and enhancements;
- technical
initiatives to roll out this version while continuing to develop
innovative new modules to meet the requirements of both general
practitioners and specialists.
- FINTECH
Division: Q3 2022 down 19.22 % to €0.45m. At
30/09/2022, down 18.77 % to €1.53m. This Division accounts for
0.89 % of total Group revenue.
The combined impact of inflation and rising
interest rates has created an environment of general uncertainty
for this business. Given the reluctance of banks in this context,
the FINTECH Division represents a solid alternative, with a mature
offering in this market and highly reputable lending partners.
Update of
Ségur
listings
While the id. by
Pharmagest - DOMILINK SSIAD and TITANLINK solutions for the
Pharmacy and Social Care categories were submitted at the end of
this summer and are still being reviewed by the French Digital
Health Agency certification board (ANS), the MédiStory 4, DOMILINK
HAD, HOSPILINK, MEDILINK and TITAN solutions for the Hospital,
Primary Care Physicians and Social Care categories have already
been certified and are eligible for funding from the public
authorities.
Equasens Group's sales
teams were among the first in the market to offer certified
software solutions and extensions for sale. At the same time, after
a strong push to file the Ségur supporting files, all the R&D
teams are now once again fully focused on deploying the Group's
solutions and developing their other specialities (the pandaLAB HUB
secure intermediation platform, the NOVIAcare programme, e-health
technological solutions, etc.).
Significant events occurring after 30
September 2022
On 5 October 2022, the
French standardisation body AFNOR awarded PANDALAB ISO 27001 and
HDS certification as a data services hosting provider for the
provision, administration and operation of health applications for
pandaLAB Pro (its secure interprofessional instant messaging
system).
In response to the growing cybersecurity
challenges, this dual certification highlights:
- PANDALAB's commitment to guarantee
its customers a high level of development quality, confidentiality
and security of their information assets,
- its strategy of improving the
coordination of healthcare through its secure intermediation
platform pandaLAB HUB by promoting interoperability between all
healthcare applications.
While continuing to
invest in business software implementation for Equasens Group and
La Coopérative WELCOOP, pandaLAB Pro is also expanding into
specific private ecosystems with the launch of the "PRIVATE TEAM"
model.
At the end of
September 2022, this solution boasted an installed base of 19,194
healthcare professional user accounts (doctors, pharmacists,
nurses, administrative staff, physiotherapists).
2022 outlook
In line with its
latest acquisitions in Europe (CAREMEDS, MULTIMEDS and I-MEDS),
Equasens Group confirms its goals of continuing to expand in this
region and developing in other healthcare sectors, for example the
specific offering for nurses, soon to be deployed.
Equasens Group is
confident in the outlook for 2022 and confirms the current level of
growth.
Financial
calendar:
- Publication of FY 2022 annual
revenue: 3 February 2023 (after the close of trading).
About Equasens
Group:
With more than 1,200 employees fulfilling a
vital role as “Citizens in the Service of Health and Well-Being”,
Equasens Group is today a key player in the European healthcare
sector, providing software solutions to all healthcare
professionals (pharmacists, primary care practitioners, hospitals,
Hospital-at-Home structures, retirement homes, health centres) in
both primary and secondary care sectors.
With operations in in France, Germany, Great
Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group is
currently developing the leading healthcare platform and a unique
ecosystem in France and Europe benefiting people by making
available the very best of technology.
Listed on Euronext Paris™ - Compartment A
Included in the Euronext Tech Leaders segment
and the European Rising Tech label Indexes: MSCI GLOBAL SMALL CAP -
GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Eligible for the Deferred Settlement Service (“Service à
Réglement Différé” - SRD) and equity savings accounts invested in
small and mid caps (PEA-PME).ISIN: FR0012882389 - Ticker
Code: EQS
For all the latest news on Equasens Group go to
www.equasens.com
CONTACTS
Analyst and Investor
Relations: Chief Administrative and Financial Officer:
Jean-Yves SAMSONTel. +33 (0) 83 15 90 67 -
jean-yves.samson@equasens.com
Media Relations:
FIN’EXTENSO - Isabelle APRILE
Tel. +33 (0)6 17
38 61 78 - i.aprile@finextenso.fr
- EQUASENS_PRESSRELEASE_20221109_Q3 2022 REVENUE_en_US
Equasens (EU:EQS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Equasens (EU:EQS)
Historical Stock Chart
From Jul 2023 to Jul 2024